Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Hepatitis C
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Hepatitis C
    Antiviral Therapy to Treat Hepatitis C Declining In the United States - (DGNews)
    TopAbstracts in Hepatitis C 11/24/2009 - (DGNews)
    TopAbstracts in Hepatitis C 11/10/2009 - (DGNews)
    Choice of Calcineurin Inhibitor Does Not Influence Outcome of Liver Transplantation in HCV-Positive Recipients: Presented at AASLD - (DGDispatch)
    What Is the Optimal Timing of Hepatitis C Antiviral Therapy Before and After Liver Transplantation? Presented at AASLD - (DGDispatch)

    News archive

     Recent webcasts/CME - Hepatitis C
    • Improving the Standard of Care for HCV Management: Available and Emerging Strategies for Optimal Patient Outcomes
    • Improving Outcomes in Hepatitis C
    • Issues in the Care of HIV and Hepatitis C Virus-coinfected Patients: Antiretroviral Pharmacokinetics, Drug Interactions, and Liver Transplantation
      Cancer, Liver, Infections, Cardiovascular Disease, and other Biologic Agents
      Treating a Patient with RA and Hepatitis B or C

      Webcasts/CME archive

       Recent cases - Hepatitis C
        Pseudoleukocytosis Secondary to Hepatitis C-Associated Cryoglobulinemia: A Case Report
        Primary Central Nervous System Lymphoma Presenting as Bilateral Uveitis in an Immunocompetent HCV+ Patient: A Case Report
        Intra-Hepatic Splenosis as an Unexpected Cause of a Focal Liver Lesion in a Patient with Hepatitis C and Liver Cirrhosis: A Case Report
        Hepatitis Following Famotidine: A Case Report
        Hepatic Splenosis Mimicking HCC in a Patient with Hepatitis C Liver Cirrhosis and Mildly Raised Alpha Feto Protein; the Important Role of Explorative Laparoscopy

        Cases archive
          




        my personal edition > hepatitis c > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Viral Load Predicts Outcome of Liver Transplant Recipients With Hepatitis C: Presented at AASLD

          By Cheryl Lathrop

          BOSTON -- November 2, 2009 -- Viral load is an important factor and can predict the outcome of patients with hepatitis C virus (HCV) after liver transplantation, for both the development of the different types of recurrent HCV and patient survival, researchers stated here at the Liver Meeting 2009, the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).

          Ivo Graziadei, Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria, and colleagues reported the findings from their study in a poster session here on October 31.

          After liver transplant, recurrent HCV infection is ubiquitous and leads to graft loss and re-transplantation for 10% to 20% of liver transplant recipients. Donor, recipient, and viral parameters are the risk factors associated with HCV recurrence.

          As there has been conflicting data reported about the viral load and the severity of recurrent HCV disease, the aim of this study was to analyse the impact of the viral load upon the severity of the recurrent HCV infection.

          The study included data from 129 patients who received liver transplants due to HCV cirrhosis between 1980 and 2006 at the Medical University of Innsbruck and, who survived more than 6 months, and had histologically proven recurrent HCV infection.

          Viral load was measured at week 2, and at months 3, 6, and 12 post-transplant (using the bDNA HCV RNA 3.0 assay by Bayer Diagnostics). There was a mean overall follow-up of 6.1 +- 3.6 years. Annual liver biopsies began in 2000; before that, biopsies were performed only in patients with elevated serum transaminases.

          The majority of patients (81.4%) had no, or only mild to moderate HCV recurrence; 18.6% developed either a cholestatic type of recurrence (8.6%) or a rapid progression to advanced fibrosis/cirrhosis (9.1%).

          Early viraemia (HCV RNA levels >6.0 log10 IU/mL) at week 2 were highly predictive for the cholestatic type of recurrence and poor patient survival. High viral loads (>6.5 log10 IU/mL) at month 3 were associated with recurrent cirrhosis of the liver allograft.

          [Presentation Title: Viral Load Predicts Outcome of Hepatitis C Patients After Liver Transplantation. Abstract 516]




        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send